For the fiscal year ending December 2025, revenue was JPY 1,257.9 billion (YoY +7.5%), operating income was JPY 598.8 billion (YoY +10.5%), and net income was JPY 434.0 billion (YoY +12.1%), achieving growth in both revenue and profits.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4519","jir_company_name":"Chugai Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-01-29","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/01\/4519-20260129-02.pdf","jir_short_summary":"For the fiscal year ending December 2025, revenue was JPY 1,257.9 billion (YoY +7.5%), operating income was JPY 598.8 billion (YoY +10.5%), and net income was JPY 434.0 billion (YoY +12.1%), achieving growth in both revenue and profits.","jir_summary":"### Overview of Earnings\nIn the consolidated financial results for the fiscal year ending December 2025, revenue reached JPY 1,257.9 billion (YoY +7.5%), operating income was JPY 598.8 billion (YoY +10.5%), and net income was JPY 434.0 billion (YoY +12.1%), marking increases in both revenue and profit. Product sales amounted to JPY 1,077.8 billion (YoY +8.0%), with the domestic market at JPY 472.4 billion (YoY +2.5%) and the overseas market at JPY 605.4 billion (YoY +12.8%), reflecting growth in overseas sales. Research and development expenses were JPY 187.6 billion (YoY +3.4%), representing 14.9% of revenue. The operating margin remained high at approximately 47.6%.\n\n### Business and Product Trends and Research & Development\nOncology products centered around the cancer domain performed steadily, with increased sales of key products such as Tecentriq and Alecensa. Overseas sales showed significant growth, particularly exports to Roche. Research and development activities remain active, with multiple new indication expansion applications and Phase III trials progressing toward 2026. The dividend policy, including the 100th anniversary commemorative dividend, was also announced, emphasizing shareholder returns.","jir_financial_highlights":"Revenue: JPY 1,257.9 billion (YoY +7.5%)\nOperating Income: JPY 598.8 billion (YoY +10.5%)\nNet Income: JPY 434.0 billion (YoY +12.1%)\nCore EPS: JPY 274.02 (Cumulative for Fiscal Year Ending December 2025) (YoY +13.6%)\nDividend per Share (Full Year): JPY 272 (Ordinary Dividend JPY 122 + 100th Anniversary Commemorative Dividend JPY 150) (Unknown)","jir_category":"","jir_hashtags":"#ChugaiPharmaceutical, #financial_summary, #JapaneseStocks","jir_key_figures":"Revenue: JPY 1,257.9 billion (YoY +7.5%)\nOperating Income: JPY 598.8 billion (YoY +10.5%)\nNet Income: JPY 434.0 billion (YoY +12.1%)","jir_meta_title":"Chugai Pharmaceutical Fiscal Year Ending December 2025 Consolidated Results: Revenue JPY 1,257.9 billion, Operating Income JPY 598.8 billion, Achieving Growth","jir_meta_description":"Supplementary materials for Chugai Pharmaceutical's consolidated financial results for the fiscal year ending December 2025 [IFRS]. Reported revenue of JPY 1,257.9 billion (YoY +7.5%), operating income of JPY 598.8 billion (+10.5%), and net income of JPY 434.0 billion (+12.1%). Features growth in overseas sales and progress in R&D.","jir_og_title":"Chugai Pharmaceutical Fiscal Year Ending December 2025 Results: Achieving Revenue and Profit Growth","jir_og_description":"Supplementary materials for Chugai Pharmaceutical's consolidated financial results for the fiscal year ending December 2025 [IFRS]. Both revenue and profits increased year-over-year, supported by strong overseas operations and research and development.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend (billion JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2024 Q1\\\",\\\"2024 Q2\\\",\\\"2024 Q3\\\",\\\"2024 Q4\\\",\\\"2025 Q1\\\",\\\"2025 Q2\\\",\\\"2025 Q3\\\",\\\"2025 Q4\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[2369,5529,8685,11706,2885,5785,9116,12579],\\\"borderColor\\\":\\\"#3e95cd\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":true}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend (billion JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2024 Q1\\\",\\\"2024 Q2\\\",\\\"2024 Q3\\\",\\\"2024 Q4\\\",\\\"2025 Q1\\\",\\\"2025 Q2\\\",\\\"2025 Q3\\\",\\\"2025 Q4\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[999,2582,4186,5420,1367,2733,4298,5988],\\\"borderColor\\\":\\\"#8e5ea2\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":true}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"net_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Income Trend (billion JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2024 Q1\\\",\\\"2024 Q2\\\",\\\"2024 Q3\\\",\\\"2024 Q4\\\",\\\"2025 Q1\\\",\\\"2025 Q2\\\",\\\"2025 Q3\\\",\\\"2025 Q4\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income\\\",\\\"data\\\":[744,1863,2958,3873,972,1944,3056,4340],\\\"borderColor\\\":\\\"#3cba9f\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":true}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Product Sales Domestic and Overseas (billion JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2024\\\",\\\"2025\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Domestic\\\",\\\"data\\\":[4611,4724],\\\"backgroundColor\\\":\\\"#f39c12\\\"},{\\\"label\\\":\\\"Overseas\\\",\\\"data\\\":[5368,6054],\\\"backgroundColor\\\":\\\"#3498db\\\"}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"position\\\":\\\"top\\\"}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"r_and_d_expense_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Research & Development Expenses Trend (billion JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2024\\\",\\\"2025\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"R&D Expenses\\\",\\\"data\\\":[1814,1876],\\\"borderColor\\\":\\\"#e74c3c\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":true}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}]","ir_related_company":6836,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-21930","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n